Erythematotelangiectatic Rosacea
Conditions
Interventions
Control Group:Basic moisturizer
Study Group:Cetaphil Soothing & Comforting Facial Cream
Sponsors
The Third Affiliated Hosptial of ChongQing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1.Male or female patients aged 18-50 years, with Fitzpatrick skin types II-IV; 2.Subjects diagnosed with erythematotelangiectatic rosacea, with a disease history of at least 1 month; 3.Primary clinical manifestations include persistent erythema, Clinician‘s Erythema Assessment (CEA) score between 3 and 4; 4.Deemed suitable for minocycline therapy as determined by a physician; 5.Subjects willing to participate in this trial and who have provided written informed consent;
Exclusion criteria
Exclusion criteria: 1.Non-erythematotelangiectatic rosacea subject; 2.Pregnant, expectant or lactating women; 3.Subjects with a history of serious systemic diseases, including tumors, bleeding and coagulation disorders, severe liver, cardiovascular and cerebrovascular diseases; 4.Subjects with mental or neurological disorders that impede cooperation or lead to unwillingness to participate; 5.Use of systemic medications for the treatment of rosacea within one month prior to enrollment; 6.Use of topical rosacea treatments within two weeks prior to enrollment; 7.Participation in another clinical trial within the past three months; 8.Undergoing facial plastic surgery, dermabrasion, laser treatments, injectable therapies, or chemical peels within one month prior to enrollment; 9.Known allergies to any skincare products being used in the study; 10.Any other condition deemed by the investigators to render a potential participant unsuitable for inclusion in the study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in a* value on Day 28; | — |
Secondary
| Measure | Time frame |
|---|---|
| a* value;Clinician's Erythema Assessment (CEA);Number of days required to achieve a 1-point reduction in Patient's Self-Assessment (PSA) score;Rosacea-Specific Quality-of-Life Instrument (RosQol);Facial red area;Stratum-corneum Hydration (SCH);Transepidermal Water Loss (TEWL); | — |
Countries
China
Contacts
Public ContactHao Fei
The Third Affiliated Hosptial of ChongQing Medical University
Outcome results
None listed